David Frendewey

This inventor holds 58 USPTO granted patents and 25 published patent applications, plus 13 CIPO patents and 22 EPO patents, primarily in Genetic Modification (CPC class C12N). Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Frendewey. Retrieved from https://idiyas.com/inventor/david-frendewey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 58 (Patent Applications = 25)

% Patents Active = 89.7

CIPO Patents = 13 (Patent Applications = 15)

EPO Patents = 22 (Patent Applications = 32)

Average Co-Inventor Count = 5.4

ph-index = 11

Forward Citations = 689(Granted Patents)

Forward Citations (Not Self Cited) = 496(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

55 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

2 out of 49

Regeneran Pharmaceuticals, Inc.

patents

1 out of 466

Alnylam Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Genetic Modification

Tauopathy Models

CRISPR Technologies

Antigen-Binding Proteins

Nuclease-Mediated Targeting

Mouse ES Cells

Fertile XY Female Mice

Genome Editing

Humanized TTR Locus

Gene Expression Screening

Self-Deleting Cassette

Targeted Locus Modification

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655430 - HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF (2026-06-16),

2. 12637698 - METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS (2026-05-26),

3. 12391920 - Models of tauopathy (2025-08-19),

4. 12342801 - Methods for producing antigen-binding proteins against foreign antigens (2025-07-01),

5. 12110502 - Models of tauopathy (2024-10-08),

6. 12065661 - Genetic modification of rats (2024-08-20),

7. 12060571 - Methods and compositions for modifying a targeted locus (2024-08-13),

8. 12041918 - Production of fertile XY female animals by silencing of genes on the Y chromosome (2024-07-23),

9. 12010979 - Non-human animals comprising a humanized TTR locus and methods of use (2024-06-18),

10. 11891618 - Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use (2024-02-06),

11. 11845957 - Models of tauopathy (2023-12-19),

12. 11820997 - Methods and compositions for the targeted modification of a genome (2023-11-21),

13. 11697828 - Methods and compositions for targeted genetic modification using paired guide RNAs (2023-07-11),

14. 11690362 - Nuclease-mediated repeat expansion (2023-07-04),

15. 11547100 - Method for screening gene expression in lincRNA-deficient mice or rats (2023-01-10),

Title: The Innovative Mind of David Frendewey

Introduction: David Frendewey is a renowned inventor based in New York, NY, known for his groundbreaking contributions to various industries.

Latest Patents: David Frendewey holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovations.

Career Highlights: With a career spanning over two decades, David Frendewey has consistently pushed the boundaries of traditional thinking, leading to the development of cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, David Frendewey has collaborated with leading companies, research institutions, and universities to bring his ideas to life, fostering a culture of innovation and creativity.

Conclusion: David Frendewey's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, leaving a lasting impact on the world of technology and beyond.

Profile summary based on public USPTO records.